Open AccessArticle
A phase I trial on LBH 589 (panobinostat), a histone deacetylase inhibitor (HDAC i) in combination with external radiotherapy for the treatment of prostate cancer, esophageal cancer and head and neck cancer.
0PDF
TL;DRAbstract
peer reviewed
Chat with Paper
AI Agents for this Paper
peer reviewed
Keywords
PanobinostatMedicineHistone deacetylase inhibitorHead and neck cancerProstate cancerCancerRadiation therapyOncology
Chat
Click to start Chat